Informationen på dette website er kun beregnet til Sundhedspersoner i Danmark

Søg

Menu

Close

Log indLog udLægemidlerTerapiområderPfizerConnectPfizerConnectArrangementerMaterialerEfteruddannelse
AboutAlopecia AreataLITFULO Mechanism of ActionSALT EvaluationEfficacyALLEGRO-2b/3 Study OverviewScalp Hair ResponsePatient-reported OutcomesEyebrow & Eyelash ResponseBefore & After ImagesSafetyALLEGRO-2b/3 Adverse ReactionsAdditional Safety ConsiderationsGetting StartedDosingScreening & MonitoringSetting Patient ExpectationsResourcesMaterialsVideos
LITFULO Mechanism of ActionLITFULO is a kinase inhibitor—it inhibits JAK3 and the TEC kinase family pathways[1-10] 

Illustration made by Pfizer based on ref. 1-2, 4-6, 8-10

 Assess the extent of scalp hair loss of alopecia areata SALT evaluation LoadingCD8+=cluster of differentiation 8 positive; IL=interleukin; JAK=Janus kinase; SALT=Severity of Alopecia Tool; TEC=tyrosine kinase expressed in hepatocellular carcinoma. ReferencesReferences:1.LITFULO (ritlecitinib) SmPC. 2.Xu H, Jesson MI, Seneviratne UI, et al. PF-06651600, a dual JAK3/TEC family kinase inhibitor. ACS Chem Biol. 2019;14(6):1235-1242. doi:10.1021/acschembio.9b00188 3.King B, Zhang X, Harcha WG, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial. Lancet. 2023;401(10387):1518-1529. doi:10.1016/S0140-6736(23)00222-2. Erratum in: Lancet. 2023 Jun 10;401(10392):1928. 4.Xing L, Dai Z, Jabbari A, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med. 2014;20(9):1043-1049. doi:10.1038/nm.3645 5.Lensing M, Jabbari A. An overview of JAK/STAT pathways and JAK inhibition in alopecia areata. Front Immunol. 2022;13:955035. doi:10.3389/fimmu.2022.955035 6.Ramírez-Marín HA, Tosti A. Evaluating the therapeutic potential of ritlecitinib for the treatment of alopecia areata. Drug Des Devel Ther. 2022;16:363-374. doi:10.2147/DDDT.S334727 7.Migita K, Izumi Y, Torigoshi T, et al. Inhibition of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway in rheumatoid synovial fibroblasts using small molecule compounds. Clin Exp Immunol.2013;174(3):356-363. doi:10.1111/cei.12190 8.Telliez JB, Dowty ME, Wang L, et al. Discovery of a JAK3-selective inhibitor: functional differentiation of JAK3-selective inhibition over pan-JAK or JAK1-selective inhibition. ACS Chem Biol. 2016;11(12):3442-3451. doi:10.1021/acschembio.6b00677 9.Eisman S, Sinclair R. Ritlecitinib: an investigational drug for the treatment of moderate to severe alopecia areata. Expert Opin Investig Drugs. 2021;30(12):1169-1174. doi:10.1080/13543784.2021.2012149 10.Guttman-Yassky E, Pavel AB, Diaz A, et al. Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers. J Allergy Clin Immunol.2022;149(4):1318-1328. doi:10.1016/j.jaci.2021.10.036
About See how LITFULO helped patients with severe alopecia areata1 EfficacyLoading Get appropriate patients started on LITFULO today Getting startedLoading
 Indication Litfulo® (ritlecitinib):
 Litfulo is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years of age and older.[Litfulo SmPC] 
 Litfulo pligttekst

Bivirkninger skal indberettes. Hvis du vil rapportere en bivirkning, kan du kontakte Pfizer på e-mail: [email protected]

 

PfizerPro kontoPfizerPro konto

Få adgang til information, materialer, efteruddannelse samt modtag kommunikation om Pfizers lægemidler og vacciner.

Log indRegisterMin profilLog ud

Informationen på dette website er kun beregnet til Sundhedspersoner i Danmark.

Denne hjemmeside er udarbejdet til dig af Pfizer Danmark.

 

© Pfizer 2023. Alle rettigheder til denne hjemmeside forbeholdes Pfizer ApS.

12 August 2025 * PP-LGF-DNK-0008
Du forlader nu Pfizer
Du forlader nu et Pfizer-drevet website. Links til alle eksterne websites leveres som en ressource til vores besøgende. Pfizer påtager sig intet ansvar for indholdet af websites, der ikke ejes og drives af Pfizer.